Ignite Creation Date:
2025-12-24 @ 7:38 PM
Ignite Modification Date:
2026-06-02 @ 7:51 PM
Study NCT ID:
NCT00702403
Status:
COMPLETED
Last Update Posted:
2017-08-10
First Post:
2008-06-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Accelerated Phase Chronic Myelogenous Leukemia | View |
| None | Adult Acute Lymphoblastic Leukemia in Remission | View |
| None | Blastic Phase Chronic Myelogenous Leukemia | View |
| None | Childhood Acute Lymphoblastic Leukemia in Remission | View |
| None | Childhood Chronic Myelogenous Leukemia | View |
| None | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Chronic Phase Chronic Myelogenous Leukemia | View |
| None | Philadelphia Positive Adult Acute Lymphoblastic Leukemia | View |
| None | Philadelphia Positive Childhood Acute Lymphoblastic Leukemia | View |
| None | Recurrent Adult Acute Lymphoblastic Leukemia | View |
| None | Recurrent Childhood Acute Lymphoblastic Leukemia | View |
| None | Relapsing Chronic Myelogenous Leukemia | View |
| None | Untreated Adult Acute Lymphoblastic Leukemia | View |
| None | Untreated Childhood Acute Lymphoblastic Leukemia | View |
Keywords: